

How can I learn more about HART?

It's easy!

If you think you might want to participate in the HART study you can contact your local study research team.

You can also contact the HSG directly by calling our toll-free number 1 (800) 487 7671 or by visiting us on the web at: www.Huntington-Study-Group.org.

Local Study Investigator

Jody Corey-Bloom, MD, PhD

University of California, San Diego

Local Study Coordinator

Jody Goldstein

858-622-5854

jlgoldstein@ucsd.edu

About the Huntington Study Group

The Huntington Study Group (HSG) is an international association of more than 200 clinical investigators, coordinators, scientists and staff from 80 participating hospitals and universities in North America, Europe, Australia and New Zealand.

The HSG is supported by the Huntington's Disease Society of America (New York, NY), the Hereditary Disease Foundation (Santa Monica, CA), HP Therapeutics, Inc. (New York, NY), and the Huntington Society of Canada (Cambridge, Ontario).

Formed in 1993, the HSG strives to advance knowledge about the cause, process and clinical impact of HD in order to develop and test promising therapeutic interventions.

For more information please visit our website at www.Huntington-Study-Group.org.

H • S • G

HUNTINGTON • STUDY • GROUP

University of Rochester
Clinical Trials Coordination Center
1351 Mt. Hope Ave. Suite 223

Phone: 1 (800) 487 7671

Web: www.huntington-study-group.org



Huntington ACR16 Randomized Trial

A clinical trial
conducted by the
HSG under the
sponsorship of
NeuroSearch AB

H • S • G

HUNTINGTON • STUDY • GROUP

NEUROSEARCH

About Clinical Trials

What is a clinical trial?

A clinical trial is a study to evaluate promising experimental treatments. They are designed to learn if new medications are safe, tolerable and effective. A clinical trial differs from an observational study in which people are examined over time without receiving any experimental drugs or treatments.

What is the HART study?

The Huntington Study Group (HSG) is conducting a study of the research medication ACR16 in persons 30 years of age and older who have clinical features of Huntington Disease (HD). HART is designed to determine general safety and tolerability and an effective dose of ACR16 as well as the effect of ACR16 on cognitive (thinking) and motor (movement) abilities in subjects with HD. Approximately 35 research centers across North America will enroll up to 220 subjects for 16 weeks each. This study is sponsored by NeuroSearch Sweden AB.



The 'who' and 'what' of the HART Study

Who can participate in HART?

In order to qualify for participation in the HART study you must:

- Be at least 30 years old or more.
- Be able to provide written informed consent.
- Have clinical features of HD and a family history of HD.
- Be able to take oral medication and be willing to comply with study-specific procedures.
- Have a caregiver or family member present for at least two of the study visits.
- Not be pregnant, lactating or intend to become pregnant.

Further restrictions on participation will be provided to you by your local study research team.

What are the study procedures?

If you are interested in participating in the HART study you will first have a visit with the study doctor to determine if you are eligible to participate. If you qualify, then you will have a second visit to evaluate your general health, mood and movement.

Blood samples will be taken at both of these visits.

During the study you will be assigned randomly to receive either one of three dosages of active study drug, or a pill that looks like the study drug but has no active ingredients. You will continue to take the trial medication or placebo for a total of 12 weeks. Your total participation time will be 16 weeks. There are 7 visits scheduled for this study to evaluate your general health, mood and movement.

What are the risks associated with participation in HART?

There are mild risks associated with taking blood samples that include pain or bruising at the site where the blood is taken. Some of the side effects noted for this medication are headache, tiredness, dizziness and nausea. Further detail on these risks is explained in the consent form. Please ask your local study research team if you have any questions or concerns.

What are the benefits to me if I decide to participate in HART?

While there may be no direct benefit to you from participating in the HART study, you may be contributing to the growing knowledge about Huntington Disease.